CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Vericel Q3 revenue beats estimates on higher MACI product sales

By Reuters News


Overview

  • US advanced therapies provider's Q3 revenue grew 26% yr/yr, beating analyst expectations

  • Q3 net income rose 179% to $14.2 mln; adjusted EBITDA margin reached 30%

  • Company raised full-year revenue and adjusted EBITDA margin guidance


Outlook

  • Vericel raises 2026 revenue guidance to $344-$346 mln from $330-$340 mln previously

  • Company raises 2026 MACI revenue guidance to $290-$292 mln from $284-$290 mln

  • Vericel raises 2026 Burn Care revenue guidance to $54 mln from $46-$50 mln


Result Drivers

  • MACI SALES - Co said MACI product sales drove revenue growth, with sixth consecutive qtr of 20%+ growth

  • BURN CARE SALES - Co said Burn Care segment, including Epicel and NexoBrid, saw record quarterly revenue and strong growth

  • SALES FORCE EXPANSION - Co attributed higher operating expenses to MACI sales force expansion and increased marketing


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$85.37 mln

$77.95 mln (8 Analysts)

Q3 EPS

$0.27

Q3 Net Income

$14.16 mln

Q3 Adjusted EBITDA

$25.20 mln

Q3 Gross Margin

73.00%

Q3 Gross Profit

$62.61 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Vericel Corporation is $59.00, about 29.7% above its November 4 closing price of $45.48

  • The stock recently traded at 56 times the next 12-month earnings vs. a P/E of 62 three months ago


Reuters Recommended Reads

  • Nov 5 - Iovance Biotherapeutics Q3 revenue rises 80% on Amtagvi demand

  • Nov 3 - Tarsus Pharmaceuticals Q3 product sales jump 64%, beating estimates

  • Nov 3 - Sweden's Eco Wave Power Q3 net loss narrows 47%, operating expenses down 25%


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.